Trials / Active Not Recruiting
Active Not RecruitingNCT06532032
A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer
A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Docetaxel Combination Therapy in Metastatic Non-small Cell Lung Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to identify the recommended Phase 2 (combination) dose (RP2CD) of the amivantamab and docetaxel combination therapy in participants with metastatic non-small cell lung cancer (NSCLC) in Phase 1 (combination dose selection); and to evaluate the antitumor effect of the combination at the selected RP2CD in participants with NSCLC without oncogenic driver mutations with disease progression on platinum-based chemotherapy and immune checkpoint inhibitor, in the Phase 2 (expansion).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Amivantamab | Amivantamab will be administered as IV infusion. |
| DRUG | Docetaxel | Docetaxel will be administered as IV infusion. |
Timeline
- Start date
- 2024-07-23
- Primary completion
- 2026-05-29
- Completion
- 2026-06-09
- First posted
- 2024-08-01
- Last updated
- 2026-04-13
Locations
15 sites across 4 countries: United States, Taiwan, Turkey (Türkiye), United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06532032. Inclusion in this directory is not an endorsement.